

Lin Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/994891/publications.pdf>

Version: 2024-02-01

63
papers

2,239
citations

394421

19
h-index

243625

44
g-index

66
all docs

66
docs citations

66
times ranked

2507
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-“Small Cell Lung Cancer: a Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2022, 28, 1127-1135.	7.0	9
2	Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901). <i>Oncologist</i> , 2022, 27, e116-e125.	3.7	6
3	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81.	2.0	9
4	Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2022, 22, 138.	4.1	7
5	An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 647-652.	1.8	8
6	Clinical and genomic features of Chinese lung cancer patients with germline mutations. <i>Nature Communications</i> , 2022, 13, 1268.	12.8	12
7	Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. <i>Cancer Medicine</i> , 2022, 11, 1081-1087.	2.8	8
8	Platinum-free chemotherapy in the new era of immunotherapy: A phase II study of camrelizumab combined with apatinib and albumin paclitaxel in advanced non-squamous NSCLC (CAPAP-lung).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9034-9034.	1.6	0
9	Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non-“small cell lung cancer: A multicenter, single-arm, phase IIb study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9106-9106.	1.6	1
10	Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9028-9028.	1.6	4
11	Prognostic analysis of doublet agent concurrent chemoradiotherapy in locally advanced cervical cancer: A propensity score analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17514-e17514.	1.6	0
12	Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20611-e20611.	1.6	3
13	ICI in combination with chemotherapy or anti-angiogenic agents as second-line or beyond treatment for advanced non-small cell lung cancer: A retrospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21057-e21057.	1.6	0
14	Central nervous system efficacy of furmonertinib versus gefitinib in patients with non-“small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9101-9101.	1.6	3
15	Safety, efficacy, pharmacokinetics of uliledlimab alone or combined with toripalimab in advanced solid tumor: Initial results of a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21123-e21123.	1.6	4
16	Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report. <i>Lung Cancer</i> , 2021, 152, 66-70.	2.0	21
17	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722.	1.6	159
18	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	2.0	40

#	ARTICLE	IF	CITATIONS
19	A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018.. Journal of Clinical Oncology, 2021, 39, e21186-e21186.	1.6	0
20	Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e21072-e21072.	1.6	3
21	Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.. Journal of Clinical Oncology, 2021, 39, e21071-e21071.	1.6	0
22	ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2021, 39, 4000-4000.	1.6	25
23	Prediction of Egfr Mutation Status in Lung Adenocarcinoma Using Multi-Source Feature Representations. , 2021, , .		6
24	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respiratory Medicine,the, 2021, 9, 829-839.	10.7	66
25	Icotinib versus chemotherapy as adjuvant treatment for stage IIâ€“III EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1021-1029.	10.7	93
26	Sintilimab, stereotactic body radiotherapy and granulocyteâ€“macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiation Oncology, 2021, 16, 177.	2.7	14
27	Nextâ€“generation sequencing assisted diagnosis of cervical metastasis in EGFR â€“mutated lung adenocarcinoma: A case report. Thoracic Cancer, 2021, 12, 2622-2627.	1.9	2
28	Effectiveness of anlotinib in patients with smallâ€“cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. Thoracic Cancer, 2021, 12, 3039-3045.	1.9	5
29	Genomic signatures define three subtypes of EGFR-mutant stage IIâ€“III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications, 2021, 12, 6450.	12.8	48
30	Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach. Frontiers in Oncology, 2021, 11, 702887.	2.8	3
31	Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. Lung Cancer, 2020, 139, 118-123.	2.0	33
32	Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage IIâ€“III (N1â€“N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study. Lung Cancer, 2020, 150, 164-171.	2.0	5
33	Silencing of long non-coding RNA SOX21-AS1 inhibits lung adenocarcinoma invasion and migration by impairing TSPAN8 via transcription factor GATA6. International Journal of Biological Macromolecules, 2020, 164, 1294-1303.	7.5	12
34	Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the Peopleâ€“s Republic of China. JTO Clinical and Research Reports, 2020, 1, 100053.	1.1	11
35	Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. Chinese Clinical Oncology, 2020, 9, 68-68.	1.2	4
36	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Translational Lung Cancer Research, 2020, 9, 269-279.	2.8	64

#	ARTICLE	IF	CITATIONS
37	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1015-1026.	1.1	58
38	Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 913.	2.8	29
39	Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. <i>Frontiers in Immunology</i> , 2020, 11, 607416.	4.8	2
40	CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9005-9005.	1.6	39
41	Effect of anlotinib in advanced small cell lung cancer (SCLC) patients relapsed within three months after second-line treatment: A subgroup analysis from a randomized, double-blind phase II trial (ALTER) Tj ETQq1 1 0.7843144gBT /Over		
42	Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations. <i>Cancer Research</i> , 2020, 80, CT127-CT127.	0.9	7
43	The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). <i>Journal of Thoracic Oncology</i> , 2019, 14, 503-512.	1.1	51
44	Irinotecan plus Sâ€ versus Sâ€ in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, openâ€labeled phase 3 trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	17
45	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	1.1	260
46	The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial. <i>Translational Lung Cancer Research</i> , 2019, 8, 575-583.	2.8	27
47	Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly. <i>Medicine (United States)</i> , 2019, 98, e14136.	1.0	0
48	Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9091-9091.	1.6	5
49	Association of microRNA-423 rs6505162 C>A polymorphism with susceptibility and metastasis of colorectal carcinoma. <i>Medicine (United States)</i> , 2018, 97, e9846.	1.0	15
50	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage IIâ€III (N1â€N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 139-148.	10.7	436
51	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. <i>BMC Cancer</i> , 2018, 18, 1082.	2.6	42
52	Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7323-7331.	2.0	31
53	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 328.	4.4	12
54	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Nonâ€Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	7.1	388

#	ARTICLE	IF	CITATIONS
55	Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study. , 2018, ,		4
56	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	2.8	7
57	An imaging/biology correlation study between radiomics features and anaplastic lymphoma kinase (ALK) mutational status in a uniform Chinese cohort of locally advanced lung adenocarcinomas.. Journal of Clinical Oncology, 2018, 36, e20540-e20540.	1.6	0
58	Adenocarcinoma of the lung with &em>EGFR &em>gene mutation and subsequent resistance mechanisms exploration: case report. OncoTargets and Therapy, 2017, Volume 10, 4517-4525.	2.0	1
59	Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIa (N1-N2) non-small-cell lung cancer (NSCLC) with <i>EGFR</i>-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).. Journal of Clinical Oncology, 2017, 35, 8500-8500.	1.6	14
60	miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9. Oncology Letters, 2016, 11, 945-952.	1.8	53
61	Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity. Tumor Biology, 2016, 37, 2275-2284.	1.8	16
62	Mefenidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction. PLoS ONE, 2015, 10, e0129283.	2.5	23
63	Fluorfenidone Offers Improved Renoprotection at Early Interventions during the Course of Diabetic Nephropathy in db/db Mice via Multiple Pathways. PLoS ONE, 2014, 9, e111242.	2.5	9